In the face of mounting antibiotic resistance, DeNovaMed is dedicated to developing new classes of antibiotics that can outsmart and overcome drug-resistant bacterial infections. Our focus extends to ‘superbug’ infections resistant to conventional treatments, posing significant challenges in healthcare settings.

DeNovaMed’s Technological Approach:

Our strategy involves the synthesis of unique antibacterial compounds that possess distinctive mechanisms of action against drug-resistant strains. Through meticulous research and ‘de novo’ molecular modeling, we design antibiotics that are not only effective against resistant bacteria but also structurally distinct from existing drugs, reducing the potential for cross-resistance and ensuring a lasting impact in the fight against these challenging infections.